<DOC>
	<DOCNO>NCT01039948</DOCNO>
	<brief_summary>During Phase 1b portion , dose-escalation AV-299 ( formerly SCH 900105 ) combination recommend dose gefitinib subject NSCLC advance solid tumor . The objective determine safety , tolerability , dose limit toxicity ( DLT ) recommend Phase 2 dose ( RP2D ) combination gefitinib Phase 2 portion . The Phase 2 open-label , 2-arm , randomize study design compare combination AV-299 ( formerly SCH900105 ) gefitinib versus gefitinib alone clinically select Asian subject previously untreated lung adenocarcinoma high likelihood harbor activate EGFR mutation . Subjects progress initial disease control gefitinib alone arm may crossover combination arm .</brief_summary>
	<brief_title>A Phase 1b/2 Study Asian Subjects With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Respiratory Tract Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Asian ethnicity . ECOG performance status 02 . Phase 1b ( ) : Diagnosis one follow unresectable NSCLC without prior therapy advance solid tumor progress standard therapy Phase 2 : Histologic cytologic confirmation unresectable locally advanced metastatic stage IIIB/IV lung adenocarcinoma least one measurable lesion , per Response Evaluation Criteria Solid Tumors ( RECISTVersion 1.1 ) . Phase 2 : Never smoker light exsmoker . Available tumor tissue determination EGFR mutational status immunohistochemistry analysis Adequate hematologic , hepatic , renal coagulation function No active central nervous system metastases Prior radiotherapy allow 14 day first dose study drug toxicity resolve ; additionally Phase 2 , ≥1 target lesion irradiate definitive progression prior radiation therapy . Agreement use effective contraception . Phase 2 : Subjects Gefitinib monotherapy arm must document CR , PR , SD ≥12 week prior disease progression order cross combination therapy arm . Phase 2 : Prior chemotherapy prior treatment epidermal growth factor receptor ( EGFR ) inhibitor , include tyrosine kinase inhibitor monoclonal antibody . There limit number therapy subject consider Phase 1b . History neoplasm entry diagnosis . Pregnancy lactation . Myocardial infarction within 6 month prior initiation study treatment . A serious active infection . Known human immunodeficiency virus infection . A serious underlying medical condition would impair ability subject receive protocol treatment . A major surgical procedure , open biopsy , significant traumatic injury . Thrombotic embolic event . Known suspected allergy/hypersensitivity agent give course trial . Any condition impairs absorption oral agent subject 's ability swallow whole pill . Diarrhea ≥ Grade 2 active Inflammatory Bowel Disease . Severe acute chronic medical , psychiatric , behavioral condition laboratory abnormality . Diagnosis interstitial lung disease . Any medication treatment prohibit protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Neoplasms Histological Type</keyword>
	<keyword>Thoracic Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>